NOV 25, 2016 8:49 AM PST

Mutation in Cancer Gene Predicts Treatment Response in Leukemia

WRITTEN BY: Xuan Pham
A chemotherapy drug that’s comparably milder than other drugs has been found to extend survival for acute myeloid leukemia patients. But the caveat, researchers say, is knowing which patient has the right genetic profile that will respond favorably to this drug.
 
Acute myeloid leukemia (AML) is cancer of the blood cells in the bone marrow. This type of cancer is highly lethal, with death rates expected to exceed 50 percent in the 20,000 people who will be diagnosed this year.
 
While the drug decitabine is considered less intense than other chemotherapy drugs, researchers noticed that some AML patients appear to respond well to decitabine. To find out why this may be the case, researchers sequenced the genetic profile of 116 AML patients. They found that those who tended to respond to decitabine also have a mutation in the cancer gene known as TP53.
 
"What's really unique here is that all the patients in the study with TP53 mutations had a response to decitabine and achieved an initial remission," said Timothy Ley, the study’s senior author. TP53 mutations are traditionally associated with poor outcome and high lethality. "With standard aggressive chemotherapy, we only see about 20 to 30 percent of these patients achieving remission, which is the critical first step to have a chance to cure patients with additional therapies.
 
It is not known exactly how a mild chemotherapy drug paradoxically works in AML cases that bear aggressive mutations in TP53. "The findings need to be validated in a larger trial," said Ley, "but they do suggest that TP53 mutations can reliably predict responses to decitabine, potentially prolonging survival in this ultra high-risk group of patients and providing a bridge to transplantation in some patients who might not otherwise be candidates."
 

Of note, decitabine is not a cure for AML. "Remissions with decitabine typically don't last long, and no one was cured with this drug," Ley explained. "But patients who responded to decitabine live longer than what you would expect with aggressive chemotherapy, and that can mean something. Some people live a year or two and with a good quality of life, because the chemotherapy is not too toxic."
 
The results of the study point to a subpopulation of AML patients who are most likely to reap benefits from decitabine. "We're now planning a larger trial to evaluate decitabine in AML patients of all ages who carry TP53 mutations," said John Welch, the study’s first author. "It's exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients."

Additional sources: Washington University School of Medicine via MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 20, 2019
Genetics & Genomics
NOV 20, 2019
Mining 'Junk' DNA for New Cancer Therapeutics
There are vast portions of the genome that don't code for protein, but researchers are learning more about how important they are....
NOV 25, 2019
Cell & Molecular Biology
NOV 25, 2019
Linking Intestinal Stem Cells with Increased Cancer Risk From a High-Fat Diet
The work, which used a mouse model, links stem cell activity with cellular fat consumption in a new way....
DEC 23, 2019
Cancer
DEC 23, 2019
Sustained weight loss over 50 reduces risk of breast cancer
Research published recently in the Journal of National Cancer Institute suggests a new form of cancer prevention: losing weight and keeping it off. This st...
JAN 03, 2020
Drug Discovery & Development
JAN 03, 2020
New Drug Combo Reverses Breast Cancer
Researchers from Georgetown University have found that combining a drug used for epilepsy, bipolar disorder, and migraines with a drug used to ease blood p...
JAN 05, 2020
Cancer
JAN 05, 2020
What does obesity have to do with skin cancer?
You might not think that obesity has anything at all to do with skin cancer. Yes, obesity has been linked as a clear risk factor to other cancers, but&hell...
JAN 15, 2020
Cell & Molecular Biology
JAN 15, 2020
Cell Division Research Reveals More About a Protein That's Elevated in Cancer
Cell division is a carefully regulated process, cancer is the result when it gets out of control....
Loading Comments...